Autolus Therapeutics (NASDAQ:AUTL) announced its earnings results on Tuesday. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.11), MarketWatch Earnings reports. The firm had revenue of $1.96 million during the quarter, compared to analyst estimates of $0.30 million.
NASDAQ:AUTL opened at $23.84 on Wednesday. The firm has a market cap of $898.87 million and a P/E ratio of -16.79. Autolus Therapeutics has a 1-year low of $19.17 and a 1-year high of $53.24.
Several equities research analysts have recently commented on AUTL shares. William Blair reaffirmed a “buy” rating on shares of Autolus Therapeutics in a report on Wednesday, April 3rd. HC Wainwright set a $45.00 price target on Autolus Therapeutics and gave the company a “buy” rating in a research report on Wednesday, February 20th. Finally, Zacks Investment Research lowered Autolus Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. Autolus Therapeutics currently has a consensus rating of “Buy” and an average price target of $44.00.
A number of large investors have recently bought and sold shares of the stock. Marshall Wace LLP raised its position in Autolus Therapeutics by 93.4% during the first quarter. Marshall Wace LLP now owns 232,931 shares of the company’s stock valued at $7,330,000 after buying an additional 112,489 shares during the period. CWM LLC acquired a new position in Autolus Therapeutics during the first quarter valued at $1,105,000. Geode Capital Management LLC acquired a new position in Autolus Therapeutics during the fourth quarter valued at $322,000. Barclays PLC acquired a new position in Autolus Therapeutics during the fourth quarter valued at $113,000. Finally, BlackRock Inc. raised its position in Autolus Therapeutics by 4,011.3% during the fourth quarter. BlackRock Inc. now owns 202,973 shares of the company’s stock valued at $6,666,000 after buying an additional 198,036 shares during the period. 40.63% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2019/05/15/autolus-therapeutics-autl-releases-quarterly-earnings-results-misses-expectations-by-0-11-eps.html.
Autolus Therapeutics Company Profile
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.
Recommended Story: Growth and Income Funds
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.